Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 450.0%, free cash flow grew 35.6% and total debt fell 6.91%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.55 0.01 +0.04%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
278×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 287.71

+8 more quarters

P/S ratio
2.45 2.43 2.38 2.18
P/FCF ratio
34.43 40.65 42.88 28.92
P/Operating CF
44.38 916.15 104.01 45.69
P/B ratio
1.87 1.83 1.72 1.48
EV/Sales
3.12 3.16 3.12 2.95
EV/EBITDA
20.26 20.71 21.16 15.56
EV/FCF
43.92 52.81 56.13 39.09
Current Ratio
2.05 2.16 2.17 2.40
Net Debt/EBITDA
12.10 10.96 (385.78) 19.77
Debt/Equity
0.59 0.61 0.61 0.60
Earnings Yield
(1.67%) (2.09%) (2.08%) 0.35%
Free Cash Flow Yield
2.90% 2.46% 2.33% 3.46%
Free Cash Flow per Share
0.49 (0.08) 0.09 0.26
Book value per Share
13.19 13.06 13.19 13.58
Free Cash Flow
244.00 (38.00) 46.00 127.00
EV/EBIT
193.59 276.30 980.37 67.96
Other line items

Show all line items

Columns are period end dates